Man Group
INO icon

Man Group’s Inovio Pharmaceuticals INO Stock Holding History

Man Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,950
Closed -$27.3K – 1871
2023
Q2 		$26.5K Buy
+4,950
New +$39.9K ﹤0.01% 1925
2021
Q1 		– Sell
-66,500
Closed -$7.06M – 1922
2020
Q4 		$7.06M Buy
66,500
+42,963
+183% +$5.72M 0.03% 611
2020
Q3 		$3.28M Sell
23,537
-8,887
-27% -$1.85M 0.01% 1014
2020
Q2 		$10.5M Buy
+32,424
New +$5.21M 0.05% 347
2018
Q3 		– Sell
-14,083
Closed -$662K – 2150
2018
Q2 		$662K Hold
14,083
– – ﹤0.01% 1725
2018
Q1 		$796K Buy
+14,083
New +$762K ﹤0.01% 1585

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Man Group's INO Position: Q3 2023 in Review

Man Group sold out of Inovio Pharmaceuticals (INO) in Q3 2023, closing a stake of 4,950 shares — an estimated $27.3K sold.

Man Group first reported a position in INO in Q1 2018 and held it in 6 quarters. The position peaked at $10.5M in Q2 2020. 124 funds tracked by Wall St. Rank hold INO as of Q3 2023.

  • Man Group reported no remaining Inovio Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Man Group sold 4,950 Inovio Pharmaceuticals shares in Q3 2023, an estimated $27.3K.
  • Man Group first reported a position in Inovio Pharmaceuticals in Q1 2018 and held it in 6 quarters.
  • Man Group's Inovio Pharmaceuticals position peaked at $10.5M in Q2 2020.
  • 124 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.